Shiseido Competitors

Shiseido (OTCMKTS:SSDOY) and GlaxoSmithKline (NYSE:GSK) are both large-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Shiseido and GlaxoSmithKline, as reported by MarketBeat.

Profitability

This table compares Shiseido and GlaxoSmithKline's net margins, return on equity and return on assets.

Volatility & Risk

Shiseido has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Valuation & Earnings

This table compares Shiseido and GlaxoSmithKline's revenue, earnings per share and valuation.

GlaxoSmithKline has higher revenue and earnings than Shiseido. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 6.6%. Shiseido pays out 15.7% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Institutional & Insider Ownership

0.1% of Shiseido shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

GlaxoSmithKline beats Shiseido on 13 of the 15 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and CSL (OTCMKTS:CSLLY) are both large-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Shiseido and CSL, as reported by MarketBeat.

Profitability

This table compares Shiseido and CSL's net margins, return on equity and return on assets.

Volatility & Risk

Shiseido has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, CSL has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Valuation & Earnings

This table compares Shiseido and CSL's revenue, earnings per share and valuation.

CSL has lower revenue, but higher earnings than Shiseido. Shiseido is trading at a lower price-to-earnings ratio than CSL, indicating that it is currently the more affordable of the two stocks.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. CSL pays an annual dividend of $0.94 per share and has a dividend yield of 0.9%. Shiseido pays out 15.7% of its earnings in the form of a dividend. CSL pays out 40.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Institutional & Insider Ownership

0.1% of Shiseido shares are held by institutional investors. Comparatively, 0.2% of CSL shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CSL beats Shiseido on 10 of the 14 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Zoetis (NYSE:ZTS) are both large-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Volatility & Risk

Shiseido has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. Shiseido pays out 15.7% of its earnings in the form of a dividend. Zoetis pays out 27.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

0.1% of Shiseido shares are held by institutional investors. Comparatively, 92.5% of Zoetis shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Shiseido and Zoetis' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for Shiseido and Zoetis, as reported by MarketBeat.

Zoetis has a consensus price target of $178.1818, indicating a potential upside of 3.87%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Shiseido.

Valuation & Earnings

This table compares Shiseido and Zoetis' revenue, earnings per share and valuation.

Zoetis has lower revenue, but higher earnings than Shiseido. Shiseido is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats Shiseido on 15 of the 17 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Bayer Aktiengesellschaft (OTCMKTS:BAYRY) are both large-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Shiseido has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Bayer Aktiengesellschaft has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Bayer Aktiengesellschaft pays an annual dividend of $0.41 per share and has a dividend yield of 2.5%. Shiseido pays out 15.7% of its earnings in the form of a dividend. Bayer Aktiengesellschaft pays out 23.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Institutional & Insider Ownership

0.1% of Shiseido shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Shiseido and Bayer Aktiengesellschaft's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Shiseido and Bayer Aktiengesellschaft, as reported by MarketBeat.

Valuation and Earnings

This table compares Shiseido and Bayer Aktiengesellschaft's top-line revenue, earnings per share and valuation.

Bayer Aktiengesellschaft has higher revenue and earnings than Shiseido. Bayer Aktiengesellschaft is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.

Summary

Bayer Aktiengesellschaft beats Shiseido on 10 of the 14 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Shiseido has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of Shiseido shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Shiseido and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Shiseido and Vertex Pharmaceuticals, as reported by MarketBeat.

Vertex Pharmaceuticals has a consensus price target of $293.4737, indicating a potential upside of 36.49%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Shiseido.

Earnings & Valuation

This table compares Shiseido and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has lower revenue, but higher earnings than Shiseido. Shiseido is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Shiseido on 14 of the 15 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Shiseido has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares Shiseido and Takeda Pharmaceutical's net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.1% of Shiseido shares are owned by institutional investors. Comparatively, 3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Shiseido and Takeda Pharmaceutical, as reported by MarketBeat.

Valuation and Earnings

This table compares Shiseido and Takeda Pharmaceutical's top-line revenue, earnings per share and valuation.

Shiseido has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.3%. Shiseido pays out 15.7% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Takeda Pharmaceutical beats Shiseido on 9 of the 13 factors compared between the two stocks.